PURPOSE: Asparaginase is an essential drug in childhood acute lymphoblastic leukemia (ALL) therapy and is frequently given for months to obtain continuous asparagine depletion. We randomly assigned patients to continuous versus intermittent pegylated-asparaginase (PEG-asp) treatment, hypothesizing there would be decreased toxicity with unchanged efficacy. METHODS:Children (median age, 4.2 years) treated for non-high-risk ALL according to the Nordic Society for Pediatric Hematology and Oncology ALL2008 protocol received fiveintramuscular PEG-asp injections (1,000 IU/m2) every two weeks and were then randomly assigned to additional three doses (6-week intervals [experimental arm], n = 309) versus 10 doses (2-week intervals [standard arm], n = 316). The primary end point was noninferior (6% margin) disease-free survival. Toxicity reduction was a secondary end point. Occurrence of asparaginase-associated hypersensitivity, pancreatitis, osteonecrosis, and thromboembolism were prospectively registered. RESULTS: After a median follow-up of 4.1 years, the 5-year disease-free survival was 92.2% (95% CI, 88.6 to 95.8) and 90.8% (95% CI, 87.0 to 94.6) in the experimental and standard arms, respectively. The 3-year cumulative incidence of any first asparaginase-associated toxicity (hypersensitivity [n = 13]; osteonecrosis [n = 29]; pancreatitis [n = 24]; thromboembolism [n = 17]) was 9.3% in the experimental arm and 18.1% in the standard arm (P = .001). Asparaginase-associated toxicity reduction was confirmed in sex- and risk-group-adjusted Cox regression analysis stratified by age (≥ 10 and < 10 years; hazard ratio, 0.48; P = .001). The experimental arm had the lowest incidences of all four toxicities, reaching significance for pancreatitis (6-month risk, 5.8% v 1.3%; P = .002). CONCLUSION: The excellent cure rates and reduced toxicity risk support the use of intermittent PEG-asp therapy after the first 10 weeks in future childhood ALL trials that apply prolonged PEG-asp therapy.
RCT Entities:
PURPOSE:Asparaginase is an essential drug in childhood acute lymphoblastic leukemia (ALL) therapy and is frequently given for months to obtain continuous asparagine depletion. We randomly assigned patients to continuous versus intermittent pegylated-asparaginase (PEG-asp) treatment, hypothesizing there would be decreased toxicity with unchanged efficacy. METHODS:Children (median age, 4.2 years) treated for non-high-risk ALL according to the Nordic Society for Pediatric Hematology and Oncology ALL2008 protocol received five intramuscular PEG-asp injections (1,000 IU/m2) every two weeks and were then randomly assigned to additional three doses (6-week intervals [experimental arm], n = 309) versus 10 doses (2-week intervals [standard arm], n = 316). The primary end point was noninferior (6% margin) disease-free survival. Toxicity reduction was a secondary end point. Occurrence of asparaginase-associated hypersensitivity, pancreatitis, osteonecrosis, and thromboembolism were prospectively registered. RESULTS: After a median follow-up of 4.1 years, the 5-year disease-free survival was 92.2% (95% CI, 88.6 to 95.8) and 90.8% (95% CI, 87.0 to 94.6) in the experimental and standard arms, respectively. The 3-year cumulative incidence of any first asparaginase-associated toxicity (hypersensitivity [n = 13]; osteonecrosis [n = 29]; pancreatitis [n = 24]; thromboembolism [n = 17]) was 9.3% in the experimental arm and 18.1% in the standard arm (P = .001). Asparaginase-associated toxicity reduction was confirmed in sex- and risk-group-adjusted Cox regression analysis stratified by age (≥ 10 and < 10 years; hazard ratio, 0.48; P = .001). The experimental arm had the lowest incidences of all four toxicities, reaching significance for pancreatitis (6-month risk, 5.8% v 1.3%; P = .002). CONCLUSION: The excellent cure rates and reduced toxicity risk support the use of intermittent PEG-asp therapy after the first 10 weeks in future childhood ALL trials that apply prolonged PEG-asp therapy.
Authors: Sumit Gupta; Cindy Wang; Elizabeth A Raetz; Reuven Schore; Wanda L Salzer; Eric C Larsen; Kelly W Maloney; Len A Mattano; William L Carroll; Naomi J Winick; Stephen P Hunger; Mignon L Loh; Meenakshi Devidas Journal: J Clin Oncol Date: 2020-04-10 Impact factor: 44.544
Authors: Stephanie B Dixon; Yan Chen; Yutaka Yasui; Ching-Hon Pui; Stephen P Hunger; Lewis B Silverman; Kirsten K Ness; Daniel M Green; Rebecca M Howell; Wendy M Leisenring; Nina S Kadan-Lottick; Kevin R Krull; Kevin C Oeffinger; Joseph P Neglia; Ann C Mertens; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Paul C Nathan Journal: J Clin Oncol Date: 2020-07-24 Impact factor: 44.544
Authors: Anjali S Advani; Eric Larsen; Kristina Laumann; Selina M Luger; Michaela Liedtke; Meenakshi Devidas; Zhiguo Chen; Jun Yin; Matthew C Foster; David Claxton; Kristin Coffan; Martin S Tallman; Frederick R Appelbaum; Harry Erba; Richard M Stone; Stephen P Hunger; Jennifer L McNeer; Mignon L Loh; Elizabeth Raetz; Naomi Winick; William Carroll; Richard A Larson; Wendy Stock Journal: Blood Adv Date: 2021-01-26
Authors: Linea N Toksvang; Kathrine Grell; Jacob Nersting; Matilda Degn; Stine N Nielsen; Jonas Abrahamsson; Bendik Lund; Jukka Kanerva; Ólafur G Jónsson; Kristi Lepik; Goda Vaitkevičienė; Laimonas Griškevičius; Petter Quist-Paulsen; Ajay Vora; Anthony V Moorman; Daniel Murdy; Martin Zimmermann; Anja Möricke; Bruce Bostrom; Jaitri Joshi; Lisa L Hjalgrim; Kim P Dalhoff; Bodil Als-Nielsen; Kjeld Schmiegelow Journal: Leukemia Date: 2021-06-26 Impact factor: 11.528